TeamDrive
RUS

RusnanoMedInvest

www.rmi.com.ru

RusnanoMedInvest (a subsidiary of RUSNANO) - was founded in March 2012 and is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. Initial funding - $ 380 mln.

The key strategic objective of RusnanoMedInvest is to create a Russian-domiciled locus of world-class expertise in venture capital fundraising, deal origination and execution in Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.

Together with U.S. life sciences venture firm Domain Associates LLC, RusnanoMedInvest is now executing a pharmaceutical project to assume not less than 20 innovative molecules to be localized in Russia. Ultimately this will significantly reduce the introduction lead time of new and innovative medicines and medical devices in Russia targeted at delivering significant therapeutic benefits and efficiencies in disease areas that are classified as socially significant complex, poorly treated and widely prevalent diseases in Russia  in cases where no domestically sourced, effective treatment methods are available today.

Media Center

  • 16 January 2018

    The coming of age of gene therapy: A review of the past and path forward

    After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the journal Science provides an in-depth and timely review of the key developments that have led to several successful gene therapy treatments for patients with serious medical conditions.

  • 16 January 2018

    Russia approves the mechanism for introducing the medicines into circulation

    A draft federal law on the introduction of medicinal products for human use into civil circulation was prepared by the Russian Ministry of Health. The bill proposes to establish a more effective legal regulation of relations associated with the elaboration, application and enforcement of requirements in the area of circulation of medicinal products for human use, namely, by establishing a mechanism for release control of medicines coming into the civil circulation in Russia.

  • 15 January 2018

    Drug discovery IT solutions will reach $5.3 billion globally by 2020

    The latest analysis, Growth Insights – Global Pharmaceutical Drug Discovery IT Solutions Market, Forecast to 2020, by Frost & Sullivan highlights the growing interest in big data analytics and artificial intelligence (AI)-based solutions.

  • 15 January 2018

    Clinical trials of Russian polio vaccine will be completed by mid-2018

    Russian scientists plan to complete the clinical trials of domestically developed inactivated polio vaccine by mid-2018 and are preparing the documents required for the registration of this drug. This was announced by Aidar Ishmukhametov, the Director of M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Products of Russian Academy of Sciences.

Read more